Arcutis Biotherapeutics Says Phase 3 Data Confirm Zoryve's Efficacy in Atopic Dermatitis
Arcutis Biotherapeutics (ARQT) said Thursday that data from two phase 3 studies reinforced the efficacy and safety of Zoryve cream for the treatment of mild to moderate atopic dermatitis, a form of eczema.
Zoryve, also known as roflumilast, was approved in July 2024 by the US Food and Drug Administration for the topical treatment of atopic dermatitis in adults and children.
An article in the Journal of American Medical Association Dermatology reported that Zoryve use showed significant improvements across multiple efficacy endpoints and in key secondary endpoints, including itch and 75% reduction in eczema area and severity index score in more than 40% of patients after 4 weeks, the company said.
Arcutis shares were up 1.8% in recent premarket activity.
Price: 10.59, Change: +0.19, Percent Change: +1.83
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available